Related Experiment Video
Updated: Mar 13, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb
Soumya Swaminathan1, Jotam G Pasipanodya2, Geetha Ramachandran1
1National Institute for Research in Tuberculosis, Chennai, India.
Background:
The role of drug concentrations in clinical outcomes in children with tuberculosis is unclear. Target concentrations for dose optimization are unknown.
Methods:
Plasma drug concentrations measured in Indian children with tuberculosis were modeled using compartmental pharmacokinetic analyses. The children were followed until end of therapy to ascertain therapy failure or death. An ensemble of artificial intelligence algorithms, including random forests, was used to identify predictors of clinical outcome from among 30 clinical, laboratory, and pharmacokinetic variables.
Results:
Among the 143 children with known outcomes, there was high between-child variability of isoniazid, rifampin, and pyrazinamide concentrations: 110 (77%) completed therapy, 24 (17%) failed therapy, and 9 (6%) died. The main predictors of therapy failure or death were a pyrazinamide peak concentration <38.10 mg/L and rifampin peak concentration <3.01 mg/L. The relative risk of these poor outcomes below these peak concentration thresholds was 3.64 (95% confidence interval [CI], 2.28-5.83). Isoniazid had concentration-dependent antagonism with rifampin and pyrazinamide, with an adjusted odds ratio for therapy failure of 3.00 (95% CI, 2.08-4.33) in antagonism concentration range. In regard to death alone as an outcome, the same drug concentrations, plus z scores (indicators of malnutrition), and age <3 years, were highly ranked predictors. In children <3 years old, isoniazid 0- to 24-hour area under the concentration-time curve <11.95 mg/L × hour and/or rifampin peak <3.10 mg/L were the best predictors of therapy failure, with relative risk of 3.43 (95% CI, .99-11.82).
Conclusions:
We have identified new antibiotic target concentrations, which are potential biomarkers associated with treatment failure and death in children with tuberculosis.
Insights
New antibiotic target concentrations for pediatric tuberculosis treatment were identified. Lower peak concentrations of pyrazinamide and rifampin predict treatment failure and death in children.
Area of Science:
- Pharmacokinetics and Pharmacodynamics
- Pediatric Infectious Diseases
- Artificial Intelligence in Medicine
Background:
- The relationship between drug concentrations and clinical outcomes in pediatric tuberculosis is not well understood.
- Optimal target concentrations for drug dosing in children with tuberculosis remain unknown.
Purpose of the Study:
- To identify key predictors of treatment failure and death in children with tuberculosis.
- To establish target drug concentrations for optimizing tuberculosis treatment in pediatric populations.
Main Methods:
- Compartmental pharmacokinetic analyses were used to model plasma drug concentrations in Indian children with tuberculosis.
- Artificial intelligence algorithms, including random forests, identified predictors of clinical outcomes from 30 variables.
- Children were monitored through therapy to determine treatment success, failure, or death.
Main Results:
- High variability in isoniazid, rifampin, and pyrazinamide concentrations was observed.
- Pyrazinamide peak concentration <38.10 mg/L and rifampin peak concentration <3.01 mg/L were significant predictors of therapy failure or death.
- Isoniazid exhibited concentration-dependent antagonism with rifampin and pyrazinamide, increasing the risk of treatment failure.
Conclusions:
- New antibiotic target concentrations have been identified for pediatric tuberculosis.
- These concentrations serve as potential biomarkers for predicting treatment failure and mortality in children with tuberculosis.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Therapeutic Drug Monitoring: Affecting Factors
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

